RGDXQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RGDXQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The historical data trend for Response Genetics's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Response Genetics Annual Data | |||||||||||||||||||||
Trend | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | |||||||||||
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | - | - | - | - | - |
Response Genetics Quarterly Data | ||||||||||||||||||||
Sep10 | Dec10 | Mar11 | Jun11 | Sep11 | Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Dec15 | |
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | - | - | - | - | - |
For the Diagnostics & Research subindustry, Response Genetics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Response Genetics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Response Genetics's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
Response Genetics's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec15 is calculated as:
For example, Response Genetics's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec15 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Dec15 (Change) | * | Current CPI (Dec15) |
= | -1.432 | / | 99.7924 | * | 99.7924 | |
= | -1.432 |
Current CPI (Dec15) = 99.7924.
Response Genetics Annual Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
200612 | 0.831 | 85.142 | 0.974 |
200712 | -0.782 | 88.616 | -0.881 |
200812 | -0.720 | 88.697 | -0.810 |
200912 | -0.651 | 91.111 | -0.713 |
201012 | -0.387 | 92.474 | -0.418 |
201112 | -0.286 | 95.213 | -0.300 |
201212 | -0.335 | 96.871 | -0.345 |
201312 | -1.802 | 98.326 | -1.829 |
201412 | -1.463 | 99.070 | -1.474 |
201512 | -1.432 | 99.792 | -1.432 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Response Genetics (OTCPK:RGDXQ) Cyclically Adjusted Price-to-FCF Explanation
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thank you for viewing the detailed overview of Response Genetics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Roberto Mignone | 10 percent owner | C/O BRIDGER MANAGEMENT, LLC., 90 PARK AVENUE, 40TH FL., NEW YORK NY 10016 |
Bridger Management Llc | 10 percent owner | 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016 |
Swiftcurrent Offshore Ltd | 10 percent owner | C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104 |
David Schreiber | director | 15 TROTTERS LANE, MONROE CT 06468 |
Sam Chawla | director | 1640 MARENGO STREET, 6TH FLOOR, LOS ANGELES CA 90033 |
Van Den Broek Richard | director | 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830 |
Kevin Roy Harris | officer: Vice President and CFO | 345 N MAPLE DRIVE, SUITE 120, BEVERLY HILLS CA 90210 |
Kirk K Calhoun | director | 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054 |
Michael Serruya | director | C/O RESPONSE GENETICS, INC., 1640 MARENGO ST., 6TH FLOOR, LOS ANGELES CA 90033 |
Thomas A Bologna | director, officer: Chief Executive Officer | 4390 US ROUTE ONE, PRINCETON NJ 08540 |
Marxe Austin W & Greenhouse David M | 10 percent owner | C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022 |
Partners Swiftcurrent | 10 percent owner | 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016 |
Bridger Capital Llc | 10 percent owner | 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016 |
Plc Glaxosmithkline | 10 percent owner | 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS |
Michael A Metzger | director | C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451 |
From GuruFocus
By gurufocus • 05-15-2009
By gurufocus 10qk • 08-22-2009
By gurufocus 10qk • 05-14-2010
By gurufocus 10qk • 11-09-2010
By GuruFocus Research GuruFocus Editor • 12-14-2009
By gurufocus 10qk • 11-16-2009
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.